Research and analysis

Impact assessment opinion: Falsified Medicines Directive 2011/62/EU

Evaluation of the Department of Health impact assessment for Falsified Medicines Directive 2011/62/EU

From:
Regulatory Policy Committee
Published
27 August 2014

Documents

PDF, 70.5 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The Regulatory Policy Committee (RPC) gives independent advice to government on the quality of analysis supporting new regulations.

Following scrutiny of an impact assessment (IA) carried out prior to a regulatory proposal, the RPC provides an 鈥榦pinion鈥� on the quality of analysis and evidence presented in the IA. This opinion then informs the decisions of ministers as to whether they proceed or not with the proposal.

Updates to this page

Published 27 August 2014

Sign up for emails or print this page

Related content